Flashcards in Update on the success of the pneumococcal conjugate vaccine Deck (10):
What is the reduction of vaccine serotype invasive pneumococcal infections since introduction of PCV7?
94% in PCV7 serotype invasive pneumococcal disease in <2yo
79% overall invasive pneumococcal disease in <2yo
What percentage of invasive pneumococcal infections are meningitis?
What is the reduction of pneumococcal meningitis since introduction of PCV7?
97% PCV7 serotype meningitis in <5yo
64% all ipneumococcal meningitis in <5yo
78% increase in non-PCV7 serotype meningitis in <5yo
What is the reduction of pneumococcal pneumonia hospitalizations since introduction of PCV7?
72% decline in lobar pneumonia in <5yo
13% decline in all-cause pneumonia in <5yo
What is the reduction of OM and myringotomy tube placements since introduction of PCV7?
17-28% reduction in OM in <2yo
16-23% decline in myringotomy tube placement in <2yo
What is the effect of replacement IPD with nonvaccine serotypes?
Non-PCV7 serotypes including 19A have increased but overall rates of pneumococcal disease have decreased
What are the trends regarding increasing complicated empyema and introduction of PCV7?
Increases started prior to introduction of PCV7 so unclear as to the cause
What is the recommended vaccine schedule for healthy children?
A two or three infant dose schedule with booster dose >12mo are equally effective in low risk children
What is the recommended vaccine schedule for high risk children?
High risk children should receive the four dose schedule